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The following results have been published (epub online 21st Jan 2016) in the Asia Pacific Journal of Clinical Oncology: 
Using a Delphi process to determine optimal care for patients with pancreatic cancer 
Elizabeth A. Burmeister, Susan J. Jordan, Dianne L. O’Connell, Vanessa L. Beesley, David Goldstein, Helen M. Gooden, 
Monika Janda, Neil D. Merrett, David Wyld, Rachel E. Neale  for The Pancreatic Cancer Clinical Working Group.  
Abstract  
Aim 
Overall 5-year survival for pancreatic cancer is ~5%. Optimising the care that pancreatic cancer patients receive may 
be one way of improving outcomes. The objective of this study was to establish components of care which Australian 
health professionals believe important to optimally manage patients with pancreatic cancer.  
Methods 
Using a Delphi process, a multi-disciplinary panel of 250 health professionals were invited to provide a list of factors 
they considered important for optimal care of pancreatic cancer patients. They were then asked to score and then 
rescore (from one (no importance/disagree) to 10 (very important/agree) the factors. The mean and coefficient of 
variation scores were calculated and categorised into three levels of importance. 
Results  
Overall 63 (66% of those sent the final questionnaire; 25% of those initially invited) health professionals from 9 
disciplines completed the final scoring of 55 statements/factors encompassing themes of presentation/staging, 
surgery and biliary obstruction, multi-disciplinary team details and oncology. Mean scores ranged from 3.7 to 9.7 with 
the highest related to communication and patient assessment. There was substantial intra- and inter- disciplinary 
variation in views about MDT membership and roles. 
Conclusion 
Overall the opinions of Australian health professionals reflect international guideline recommended care; however 
they identified a number of additional factors focusing on where patients should be treated, the importance of clear 
communication and the need for multi-disciplinary care which were not included in current clinical practice 
guidelines. Differences in priorities between specialty groups were also identified.    
Introduction   
Pancreatic cancer is the 10th most commonly diagnosed cancer in more developed regions of the world. In Australia 
it is the 6th most common cancer diagnosis and the 4th leading cause of cancer related death.[1]  People diagnosed 
with pancreatic cancer have the poorest prognosis of any cancer. One-year survival is currently 15% and five-year all-
stage survival for pancreatic cancer in Australia is 5.2%, which mirrors other western countries.[2, 3]  Current 
projections suggest that it will be the second leading cause of cancer death within 10 years as survival from other 
cancers improves.[4, 5]  
Provision of optimal care increases the likelihood of desired health outcomes.[6, 7] To facilitate this clinical practice 
guidelines/recommendations for pancreatic cancer have been published in Europe[8-11] and the USA.[12] However, 
the extent to which health professionals in the field agree with the guidelines, and if they consider all elements of the 
guidelines equally important is not known. In addition, guidelines may not cover some clinical situations or aspects of 
care that health professionals believe to be necessary for optimal management.[13] Assessing the elements of care 
that specialist clinicians consider to be important for patients with pancreatic cancer and assessing whether these 
elements are evidence-based could assist in the modification of guidelines and/or identify areas where system 
changes or clinician education could help to improve patient outcomes.  
One way of harnessing the opinions of a group of specialists is to use a Delphi process.  This method has been used 
facilitate clinical consensus in a variety of medical situations.[14-16] It begins with open-ended questions soliciting 
information from a panel of experts in the field.[17] This is followed by ranking or scoring of the derived statements 
by the panel according to set criteria. The combined resultant scores/rankings are fed back to the panel members 
who are then invited to re-score the statements. The process is conducted anonymously, preventing domination of 
individuals and iterations of the scoring and feedback process repeated until consensus is reached or negligible 
change in scores is noted. 
The aim of this study was to use a Delphi process to establish components of care which Australian health 
professionals believe are important to optimally manage patients diagnosed with pancreatic cancer. 
Methods 
The Delphi process 
We used the literature, personal contacts and professional groups, including the Australian Pancreatic Cancer 
Genome Initiative [18] and Cancer Council Australia, to identify health professionals involved in the care of pancreatic 
cancer patients from across Australia. We emailed these clinicians inviting them to participate and also asked them to 
nominate other clinicians who may be interested in participating. The panel consisted of surgeons, medical 
oncologists, radiation oncologists, gastroenterologists, palliative care specialists, nurses, allied health professionals, 
interventional radiologists and general practitioners. These experts were initially asked (online) to “...list all/any 
factors you consider important in the care of patients with suspected or confirmed pancreatic cancer.” They were 
also asked about their specialty and years in practice. 
The responses to the open-ended question were used to develop the quantitative questionnaire. Each response was 
grouped with those of similar themes and we eliminated duplicate statements. This process was done independently 
by two authors (EB and RN) and a structured list of statements was developed. Where possible, statements were 
used as written by participants. Some statements with similar inferences required merging to avoid duplication; these 
were discussed within the study team to avoid corrupting their original meanings. 
Via email, we invited panel members to complete the quantitative questionnaire. They were asked to rate the 
importance of, or their level of agreement with, each statement on a scale of one (no importance/disagree) to 10 
(very important/agree). Panel members could record ‘no opinion’ for statements they felt were beyond their scope of 
expertise. We provided the mean and median scores for each statement from the initial questionnaire to those who 
had responded to either the open-ended question or the first quantitative questionnaire and asked them to re-score 
the statements in light of this information. 
Analyses 
The mean and coefficient of variation (CV) were calculated for each statement using the scores for all participants and 
also stratified according to specialty. The CV is the ratio of the standard deviation (SD) to the mean and gives the 
relative magnitude of the SD; it was multiplied by 10 for ease of reporting.  
Using a priori criteria each statement was categorized based on the mean score and CV as follows: 
Mean 9 - 10; CV < 4: very important  
Mean 6 – 8.9; CV < 4: moderately important  
Mean 1- 5.9; CV < 4: unimportant   
Any mean; CV ≥ 4: unable to agree. 
We used analyses of variance (ANOVA) to assess differences between the specialty groups. 
Ethics   
The Human Research Ethics Committees of the QIMR Berghofer Medical Research Institute and the University of 
Queensland approved this study.  Completion of questionnaires was considered to imply consent. 
Results  
In June 2013, 250 health professionals involved in the care of pancreatic cancer patients were invited by email to 
complete the initial open-ended question (Figure 1). Of these, 78 (31%) replied and suggested a total of 380 
overlapping items that they considered important in the care of pancreatic cancer patients. These were reduced to 55 
items that encompassed the following themes: presentation and staging; surgery and biliary obstruction; the 
management team (including multi-disciplinary team (MDT) details); oncology; and other (such as enrolling patients 
in clinical trials and establishing a national pancreatic cancer prospective database). The list of 55 items was then sent 
to the original 250 health professionals, irrespective of whether or not they responded to the first open-ended 
question.  Following scoring of the initial items, the statements were resent to the 96 health professionals who had 
responded during round 1 or round 2. Of these, 63 (66% of those sent the final questionnaire; 25% of those initially 
invited) rescored the items.  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Consort diagram for the number of health professionals participating in the modified Delphi process 
 
Specialties of the participants invited included surgery (n = 56; 22%), medical oncology (n = 43; 17%), allied health and 
nursing (n = 40; 16%), gastroenterology (n = 29; 12%), palliative care (n = 28; 11%), radiation oncology (n = 13; 5%), 
and others (n = 41; 16%) which included interventional radiology, general practice, gerontology and medicine (Figure 
2).  The response proportion to the final questionnaire ranged from 10% (other) to 54% (radiation oncology).  The 
specialties of the final questionnaire respondents were: 22% - medical oncology, 18% - surgery, 19% - palliative care, 
18% - allied health and nursing, 11% - radiation oncology and 6% from each of gastroenterology and others. Seventy-
six respondents to the initial open-ended questionnaire (97%) described their clinical experience. Of these 12, (16%) 
reported more than 20 years treating patients with pancreatic cancer and treating more than ten patients each year.  
The majority of respondents treated more than 10 patients each year ( n = 43, 57%) and years of experience were 
reported as less than 10 years, 10 to 20 years and more than 20 years by 30 (39%), 25 (33%) and 21 (28%) clinicians 
respectively. 
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 Figure 2: Numbers of invited and final responders by specialty 
Based on the initial scores, 8 of the 55 statements (15%) were classified as very important and 33 (60%) as 
moderately important. The CV was greater than 4 for 14 (25%) statements, including 8 that were considered 
unimportant. No items where the CV was less than 4 were classified as unimportant. Only two statements “All 
patients should have a full physical examination, geriatric assessment if elderly, assessment of comorbidities and 
performance status prior to any treatment” and “Patients should be fully aware of the risks and benefit of 
interventions prior to any treatment” were given a moderately-high or higher score by all participants. 
The mean scores for almost half the statements (n = 24; 44%) increased between surveys but were unchanged for 17 
statements (31%), and decreased for 14 (25%) statements. The majority (n = 30; 55%) of CVs remained the same 
between surveys; 11% (n = 6) increased and 35% (n = 19) decreased between surveys. 
Statements scores according to clinician specialty are displayed below within thematic categories and by score of 
importance (Table 1). 
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Table 1: Final scores for all statements by specialty 
 
 
Surgery 
Gastro-
enterology 
Medical 
Oncology 
Radiation 
Oncology 
Allied  
Health & 
Nursing 
Palliative 
Care 
Other Total 
 n† Mean (Coefficient of Variation) 
Presentation and Staging (n =  13 statements)          
aAll patients should have a full physical examination, geriatric 
assessment if elderly, assessment of comorbidities and performance 
status prior to any treatment 
59 8.9 (2) 10.0 (0) 9.2 (1) 9.1 (1) 9.0 (2) 9.3 (2) 8.8 (2) 9.2 (2) 
aStandard guidelines for staging should be developed 60 8.5 (3) 10.0 (0) 9.4 (1) 9.1 (1) 9.3 (1) 8.6 (2) 8.8 (2) 9.1 (2) 
bAll patients should have a triple phase/ pancreas protocol CT scan for 
staging 
55 9.5 (1) 10.0 (0) 8.9 (1) 9.0 (1) 9.3 (1) 7.6 (4) 8.5 (2) 8.9 (2) 
bAll patients should have an initial TNM stage recorded 59 7.9 (3) 10.0 (0) 9.1 (1) 8.6 (2) 9.1 (1) 8.4 (2) 8.3 (2) 8.7 (2) 
bStandard guidelines should be developed to determine which 
patients would benefit from transfer to a tertiary centre 
61 8.2(2) 10.0 (0) 7.7 (3) 9.0 (1) 8.5 (2) 8.7 (2) 6.5 (2) 8.3 (2) 
bTissue diagnosis should be obtained where possible 59 7.2 (3) 6.2 (8) 8.9 (2) 9.1 (1) 8.9 (2) 8.3 (2) 8.3 (2) 8.3 (3) 
bAll patients should have access to ERCP and EUS facilities 57 7.4 (3) 10.0 (0) 8.2 (2) 7.9 (2) 9.2 (1) 7.8 (3) 7.8 (3) 8.2 (2) 
bA laparoscopy should be performed if resectability is uncertain 52 7.1 (4) 9.5 (1) 8.0 (3) 8.7 (1) 8.0 (1) 7.9 (2) 6.8 (2) 7.9 (2) 
bAll patients presenting with ongoing epigastric/back pain should 
have a CT as part of the initial investigations 
58 8.0 (3) 8.0 (4) 7.6 (3) 7.7 (1) 8.2 (2) 8.5 (1) 6.0 (2) 7.8 (2) 
bGeneral practitioners should coordinate the initial workup 59 7.3 (2) 7.0 (3) 6.4 (3) 5.9 (4) 7.1 (4) 7.2 (3) 7.3 (2) 6.8 (3) 
cIf disease appears to be localised a PET scan should be performed 56 5.1 (4) 8.4 (3) 6.1 (5) 7.7 (2) 7.4 (3) 8.4 (2) 6.8 (3) 6.9 (4) 
cAll patients should have an EUS 56 6.2 (5) 6.6 (6) 6.4 (3) 5.4 (4) 7.2 (3) 5.5 (4) 5.0 (6) 6.1 (4) 
cAll patients presenting with ongoing epigastric or back pain should 
have a CA19.9 blood test 
56 5.9 (6) 4.0 (8) 4.6 (7) 4.3 (6) 5.3 (2) 5.3 (4) 4.5 (1) 4.9 (6) 
          
Surgery and biliary obstruction (n = 9 statements )          
aAll patients with a small lesion and technically resectable disease 
plus adequate performance status should be offered a resection 
57 9.2 (1) 10.0 (0) 9.1 (1) 9.3 (1) 10.0 (0) 8.8 (1) 8.7 (2) 9.2 (1) 
aResectability should be assessed and surgery performed by surgeons 
who perform more than 5 pancreatic surgeries per year 
53 8.7 (2) 10.0 (0) 8.7 (2) 9.3 (1) 9.2 (2) 8.8 (1) 8.5 (2) 9.0 (2) 
bSurgery should take place in tertiary institutions where > 15 
resections are performed annually 
57 7.5 (4) 10.0 (0) 8.4 (2) 9.0 (1) 9.4 (2) 8.5 (2) 8.5 (2) 8.6 (2) 
bBiliary obstruction should routinely be managed endoscopically in 
non-resectable patients 
50 8.2 (3) 9.0 (2) 8.6 (1) 8.4 (1) 8.3 (1) 7.5 (2) 8.0 (2) 8.2 (2) 
cPatients with resectable disease should not be stented prior to 
surgery unless surgery is delayed 
42 5.7 (5) 9.6 (1) 5.6 (5) 7.5 (2) 9.0 (0) 7.1 (3) 7.0 (0) 6.8 (4) 
cA self-expandable metallic stent (SEMS) should be used instead of a 
plastic stent if biliary drainage is indicated prior to surgery 
36 5.7 (6) 7.2 (5) 6.9 (3) 6.5 (2) 9.0(-) 6.8 (3) 5.5 (1) 6.6 (4) 
cPotential for coeliac plexus block should be discussed before any 
surgical procedure 
41 3.3 (6) 6.6 (5) 5.9 (4) 5.5 (6) 9.0 (-) 7.2 (2) 7.0 (-) 5.8 (5) 
cBiliary obstruction should be managed surgically if performance 48 5.2 (4) 2.2 (8) 4.5 (3) 4.8 (3) 5.5 (1) 5.7 (4) 6.0 (5) 4.8 (4) 
  
Surgery 
Gastro-
enterology 
Medical 
Oncology 
Radiation 
Oncology 
Allied  
Health & 
Nursing 
Palliative 
Care 
Other Total 
 n† Mean (Coefficient of Variation) 
status and prognosis are satisfactory in non-resectable patients 
cPotentially resectable patients should not have a tissue biopsy prior 
to surgery 
46 5.3 (5) 3.6 (11) 4.5 (5) 3.4 (4) 4.5 (2) 5.3 (4) 6.0 (5) 4.7 (5) 
          
Oncology and Other (n = 14 statements )          
aPatients should be fully aware of the risks and benefit of 
interventions prior to any treatment 
63 9.6 (1) 10.0 (0) 9.7 (1) 9.0 (2) 10.0(0) 9.7 (1) 9.3 (1) 9.7 (1) 
aPatients should be advised of the limitations of chemotherapy 61 9.5 (1) 10.0 (0) 9.5 (1) 9.1 (1) 9.9 (0) 9.6 (1) 9.0 (2) 9.5 (1) 
aCareful attention to pain control is important, using nerve blocks if 
required 
58 8.3 (2) 10.0 (0) 9.1 (1) 9.1 (1) 9.9 (0) 9.6 (1) 9.3 (1) 9.3 (1) 
bAll patients should have a collaborative generalist/ specialist care 
model 
61 7.4 (4) 9.0 (2) 8.7 (1) 9.0 (1) 9.9 (0) 9.3 (1) 8.8 (1) 8.8 (2) 
bEntry into a clinical trial should be considered for all patients 57 7.7 (3) 8.8 (2) 9.4 (1) 9.1 (1) 9.5 (1) 8.3 (3) 8.3 (2) 8.8 (2) 
bApart from surgery, all treatment should occur as close to the 
patient's home as possible 
62 9.3 (1) 9.8 (0) 8.7 (2) 7.1 (3) 9.7 (1) 8.7 (3) 7.3 (4) 8.8 (2) 
bAll pancreatic cancer patients' details should be entered into a 
prospective database 
60 9.1 (2) 9.8 (0) 8.4 (2) 8.7 (1) 8.7 (2) 8.3 (2) 8.0 (2) 8.7 (2) 
bTissue should be routinely banked 51 9.2 (1) 9.2 (1) 8.9 (1) 6.8 (5) 9.8 (1) 7.1 (4) 9.0 (1) 8.5 (2) 
bAll patients should be offered adjuvant therapy post operatively, 
assuming performance status is adequate 
52 7.7 (4) 8.0 (3) 9.0 (1) 7.9 (2) 9.3 (1) 7.5 (2) 7.5 (1) 8.1 (2) 
bCreon prescription should be considered for all patients 51 9.0 (1) 6.2 (5) 8.0 (2) 6.8 (4) 8.8 (1) 7.9 (2) 6.5 (3) 7.9 (3) 
bAll patients should have access to new drugs 59 7.2 (3) 8.2 (2) 7.9 (2) 7.7 (3) 8.9 (2) 7.2 (3) 7.5 (2) 7.7 (3) 
bBorderline resectable cases should be considered for neo-adjuvant 
therapy 
51 6.8 (4) 8.8 (1) 6.9 (3) 8.0 (2) 9.0 (1) 7.3 (2) 8.0 (0) 7.5 (3) 
bBiomarkers should be used as prognosis and management tools 51 7.7 (3) 7.8 (4) 7.4 (3) 7.2 (3) 8.7 (1) 6.6 (3) 8.5 (2) 7.4 (3) 
bAll patients should have access to conformal radiotherapy 52 6.2 (3) 8.3 (3) 6.6 (4) 8.9 (1) 7.5 (3) 7.5  (2) 7.0 (0) 7.2 (3) 
          
MDT  and Referrals (n = 19 statements )          
aAll patients with potentially resectable disease should be referred to 
an hepato-biliary surgeon 
59 9.9 (0) 8.2 (5) 9.6 (1) 9.7 (1) 10.0 (0) 8.7 (2) 7.8 (3) 9.3 (2) 
aTumour resectability should be assessed by a MDT at a tertiary 
hospital 
60 8.4 (2) 10.0 (0) 9.3 (1) 9.1 (1) 9.6 (1) 8.4 (1) 7.7 (3) 9.0 (1) 
bMDT meetings should include palliative care specialists 63 8.5 (2) 7.2 (4) 8.2 (2) 8.9 (1) 9.6 (1) 9.3 (2) 9.0 (1) 8.7 (2) 
bSymptom management should be discussed at MDT meetings 63 6.8 (4) 9.0 (2) 7.7 (3) 8.9 (1) 9.5 (1) 9.2 (1) 8.8 (1) 8.5 (2) 
bEach patient should have a care-coordinator assigned with an 
individualised treatment/ clinical plan 
62 7.8 (2) 9.6 (1) 8.2 (2) 8.7 (1) 9.5 (1) 8.3 (1) 8.0 (3) 8.5 (2) 
bTertiary hospital MDTs should be involved in the care of patients 
from smaller centres (via video-conferencing etc if necessary) 
62 8.9 (1) 10.0 (0) 7.8 (2) 8.9 (1) 9.4 (1) 8.1(2) 7.3 (2) 8.5 (2) 
  
Surgery 
Gastro-
enterology 
Medical 
Oncology 
Radiation 
Oncology 
Allied  
Health & 
Nursing 
Palliative 
Care 
Other Total 
 n† Mean (Coefficient of Variation) 
bMDT meetings should include allied health professionals 61 7.4 (4) 9.0 (1) 7.8 (3) 8.7 (1) 9.1 (2) 8.8 (1) 9.0 (1) 8.4 (2) 
bAll patients should be presented to a MDT 63 7.1 (5) 10.0 (0) 8.1 (2) 8.9 (1) 9.7 (1) 7.3 (4) 7.3 (1) 8.3 (3) 
bPatients requiring diabetes management should be seen by a 
diabetic educator 
63 7.8 (3) 9.4 (1) 8.8 (1) 7.6 (2) 9.1 (1) 7.3 (3) 8.3 (2) 8.3 (2) 
aAll patients should be offered psychosocial support 62 6.7 (3) 9.4 (1) 8.0 (3) 6.7 (3) 8.8 (3) 8.6 (2) 7.8 (3) 8.0 (3) 
bAll patients should see a medical oncologist 58 8.2 (3) 7.6 (4) 8.1 (2) 8.0 (2) 8.3 (4) 7.2 (4) 7.8 (3) 7.9 (3) 
bA specialist HPB surgeon should be the initial/primary specialist 
unless the patient has obvious metastases 
57 7.7 (3) 7.6 (3) 7.6 (2) 6.6 (4) 8.1 (3) 6.4 (3) 7.3 (3) 7.3 (3) 
bAll patients should be referred to a dietitian soon after diagnosis 61 6.5 (3) 8.2 (4) 7.9 (2) 7.1 (1) 7.8 (4) 7.0 (2) 6.3 (2) 7.3 (3) 
cAll patients should be referred to a social worker 60 5.9 (4) 7.0 (4) 6.4 (4) 5.0 (3) 6.9 (5) 6.6 (2) 7.3 (3) 6.4 (4) 
cAll patients should be referred to a physiotherapist 60 4.9 (6) 4.3 (5) 5.1 (4) 3.8 (3) 5.1 (4) 4.9 (5) 5.0 (3) 4.8 (4) 
cAll patients should be referred to an occupational therapist 59 4.3 (7) 5.8 (7) 4.8 (5) 4.7 (4) 4.1 (5) 5.3 (4) 4.8 (2) 4.7 (5) 
cPatients should only be referred to palliative care when they have 
confirmed metastatic disease 
59 6.7 (3) 4.2 (8) 5.4 (4) 6.5 (2) 7.1 (4) 5.5 (5) 7.0 (3) 6.0 (4) 
cOnly patients who are potentially suitable for resection should be 
presented to a MDT 
61 5.1 (7) 1.2 (4) 4.3 (6) 2.0 (5) 1.8 (7) 4.3 (5) 4.8 (4) 3.6 (7) 
cOn diagnosis all patients should be referred to palliative care 61 2.7 (10) 2.8 (8) 3.6 (5) 3.1 (5) 4.6 (6) 6.1 (5) 4.3 (7) 4.0 (6) 
          
CV = coefficient of variation     PET = Positron emission tomography;  EUS = Endoscopic Ultrasound;  MDT = Multi-disciplinary team 
a all agree important (9 +);  b all agree moderately important (6 - 8.9),  c unable to agree (CV ≥4)  † Number of observations/respondents with an opinion “Other” 
specialty group includes interventional radiologists, general practitioners and physicians. 
Presentation and Staging:  
Almost 25% of the statements derived from the initial open-ended question related to presentation 
and staging (n = 13; 24%).  The need to conduct a full physical assessment prior to treatment and to 
develop standard staging guidelines were both rated as very important.  The panel did not reach 
consensus about the value of positron electron tomography (PET) scans, endoscopic ultrasounds 
(EUS) or carbohydrate antigen 19.9 (CA19.9) as staging tools, with evidence of variability in the rated 
importance of these statements both between and within specialty groups. Palliative care specialists 
rated the value of PET scans more highly than surgeons (mean scores 8.4 and 5.1 respectively, p = 
0.03) and had a lower CV (2 versus 4). 
Surgery and biliary obstruction:  
The 9 statements related to surgery and biliary obstruction had the fewest responses with some high 
proportions (9 – 91%) of the allied health, nursing and “other” groups indicating no opinion due to 
lack of expertise in the area.  Amongst those who did respond, the statements "all patients with a 
small lesion and technically resectable disease plus adequate performance status should be offered 
a resection" and "Resectability should be assessed and surgery performed by surgeons who perform 
more than 5 pancreatic surgeries per year", were classified as very important. Consensus was not 
reached for 5 statements. Allied health /nursing and palliative care specialists rated the statement 
“Potential for coeliac plexus block should be discussed before any surgical procedure” much higher 
than the surgical specialists (scores 9.0, 7.2 and 3.3 respectively, p = 0.02).  
Referrals and Multi-disciplinary team (MDT):  
Over a third of the survey statements (n = 19; 35%) referred to when and where treatment should 
occur, and which specialists should be involved. The statements "all patients with potentially 
resectable disease should be referred to a hepato-biliary surgeon" and "tumour resectability should 
be assessed by a MDT at a tertiary hospital" were thought very important with overall mean scores 
of 9.3 and 9.0 respectively. 
No overall or within-specialty consensus was reached for the statement “On diagnosis all patients 
should be referred to palliative care” (CV = 6). There was a significant difference in the scores 
between palliative care and surgical specialists with mean scores of 6.1 and 2.7 respectively, (p = 
0.03). Similarly, the panel did not agree on which patients should be presented at MDT meetings, 
with high inter- and intra-specialty variability.  
Although surgeons and gastroenterologists had significant variation within their specialty groups (p < 
0.001) they thought it less important that “MDT meetings should include palliative care specialists” 
and that “symptom management should be discussed at an MDT” than allied health, nursing and 
palliative care specialists (p = 0.02). 
Oncology and Others:  
All the 14 oncology and "other" statements were classified as moderately or very important with 
participants able to reach consensus and ranking none as unimportant. 
The statements that “patients should be fully aware of risks and benefits of interventions prior to 
any treatment” and “patients should be advised of the limitations of chemotherapy” were the 
highest scoring statements with total mean scores of 9.7 and 9.5 respectively and little variability 
across specialty.  
Radiation oncologists regarded access to conformal radiotherapy as more important than other 
health professionals. Surgeons scored the statement "all patients should have a collaborative 
generalist/specialist care model" lower than all other health professional groups. This difference 
between surgical and allied health/nursing specialists was statistically significant (p = 0.03). 
Gastroenterology, palliative care and allied health and nursing specialists rated the statement 
“careful attention to pain control is important, using nerve blocks if required” more highly than 
surgeons (p = 0.03). 
Discussion 
We used a Delphi process to identify factors that health professionals from a range of disciplines 
consider important in the care of patients with pancreatic cancer. As expected, many of the items 
rated as important are consistent with existing evidence-based clinical guidelines, but there were 
also items rated as important by health professionals that are not considered by guidelines. 
Furthermore, for some consensus-based or expert opinion-based items included in guidelines 
agreement on the importance of these between the health professionals we surveyed was not 
reached. We also found that the rating of particular issues varied substantially by clinical discipline. 
Clinical guidelines have been developed by peak bodies in Europe and the USA, most notably the 
National Comprehensive Cancer Network (NCCN)[12] and the European Society for Medical 
Oncology (ESMO),[9, 11] which describe clinical pathways from diagnosis to treatment for patients 
with pancreatic cancer. In Australia no national clinical practice guidelines have been developed that 
are specific to the care of patients with pancreatic cancer.  
Comparing current guidelines with the opinions of clinicians working in the field identified some 
areas requiring further clarification, in particular the diagnosis and staging of pancreatic cancer. 
Respondents in this study rated highly the need for development of standard guidelines for staging. 
This was underscored by the very high variability in responses about the value of PET, CA19.9 and 
EUS. Lack of clarity about PET is also apparent in the guidelines, with NCCN stating that it is unclear if 
PET is useful and ESMO guidelines recommending PET not be used. Both organisations recommend 
that CA19.9 should only be used in treatment monitoring and that EUS be used as an adjunct to a 
pancreatic protocol computerised tomography (CT) or magnetic resonance imaging (MRI) only in 
those without biopsy-proven metastases. The high variation in scores for EUS amongst our 
participants may result from the inclusion of the words “all patients” in the statement as those with 
confirmed metastases would not benefit from the procedure.    
It is notable that of the 55 items derived from panel members’ responses, approximately half related 
in some way to access to treatment, where treatment should occur or who should be involved in 
different treatment aspects. This may be a recognition that pancreatic cancer patients require highly 
specialised care and the provision of treatment at specialist centres might improve outcomes. This 
could also reflect the substantial geographical dispersion of the Australian population and the 
finding of a trend towards poorer survival in rural and remote areas.[19] The study participants 
agreed that patients should be managed as close to home as possible, but that standard guidelines 
should be developed to determine who would benefit from transfer to a tertiary centre. Improved 
access through video-link to tertiary centres was also considered important. Telehealth aims to 
remove barriers to accessing medical services for residents of rural and remote Australia,[20] and 
there are International and Australian recommendations around its use.[21] The Queensland state 
Department of Health estimates that use of Telehealth would reduce health costs by 30% [22] and is 
currently under-used throughout Queensland.[23] 
Access to specialist surgical management was particularly highlighted. There was high agreement 
that all patients with potentially resectable disease should be assessed by a hepatobiliary surgeon, 
ideally as part of a multidisciplinary team. The need for multidisciplinary assessment of resectability 
is specifically stated in guidelines[12] and has been shown to improve surgical mortality rates[24] 
but it is unclear to what extent this currently occurs. Respondents also agreed that pancreatic cancer 
resections should occur in high-volume centres, reflecting guideline recommendations although 
definitions of high-volume vary across guidelines. The cut-off recommended by our panellists was 
consistent with the NCCN guidelines (15 surgeries/year). However, the National Cancer Institute 
(NCI) guidelines classify hospitals carrying out > 5 resections/year as high-volume and the British 
Society of Gastroenterology (BSG) guidelines[25] do not give a value, but rather recommend that 
surgery be carried out in ‘specialist centres’. The evidence available suggests different values (range 
5 - 19) for high-volume classification.[26, 27] Few data support a role for surgeon volume 
independent of hospital volume,[27, 28] probably because these are highly correlated, but our 
participants nevertheless felt pancreatic resections should be undertaken by surgeons performing 
more than 5 per year. These data clearly show that clinicians feel that centralisation of surgical care 
for pancreatic cancer is important. In the USA, hospital volume for pancreatectomies more than 
tripled between 2000 and 2008 with the median volume increasing from 5 to 16[26] whereas in 
Australia volume is increasing but resections are still performed in low-volume hospitals.[29, 30] 
Multidisciplinary care has become the accepted standard for cancer patients and has been shown to 
improve treatment access and timeliness.[7] [31] However, systematic review evidence suggests 
there is substantial variability in the way MDT meetings are incorporated into patient care[32] and 
this is reflected in our data, which show that clinicians value multidisciplinary care but vary in their 
views about the function of MDTs in the management of patients with pancreatic cancer. For 
example, in contrast to other specialties, surgeons were less likely to agree that all patients should 
be presented to MDTs and more likely to indicate that only potentially resectable patients should be 
presented to MDTs. The NCCN guideline also suggests that only patients without metastatic disease 
be presented at MDT meetings. However, The European Partnership for Action Against Cancer 
(EPAAC) recommend in their MDT policy document[33] that MDTs co-ordinate cancer care at all 
stages.  While there was strong consensus among our panellists across all specialties that palliative 
care specialists should be present at MDT meetings, the presence of allied health professionals was 
not consistently rated as important by surgeons. This may reflect the fact that surgeons lead most 
MDT meetings and may prioritise surgical and medical issues over psychosocial concerns.[34] EPAAC 
guidelines emphasise the need for MDTs to address the supportive care and psychosocial needs of 
their patients. They also emphasise the need for coordination across different disciplines to achieve 
continuity of care. While our Delphi process identified the importance of care coordination, the 
reality is that in Australia there is considerable variability in the way that the coordination role is 
implemented.[35] Adopting system-wide policies regarding MDTs and care coordination may be one 
way of improving the management of patients with pancreatic cancer. 
The two top-scoring items in our study related to patient communication. Both items emphasised 
the importance of ensuring that patients are aware of the risks, benefits and limitations of 
treatment.   While this should be standard in all clinical situations, it is particularly important for 
patients with pancreatic cancer where surgery can result in significant morbidity and, even with 
successful resection, median survival is poor at ~20 months.[36] In addition, current chemotherapy 
regimens have limited survival benefit and a USA national cohort study showed that about three 
quarters (69 - 81%) of patients with advanced cancer did not understand that the chemotherapy 
they were receiving was unlikely to result in cure.[37]   
Up to 75% of patients with advanced pancreatic cancer report pain and it is one of the major factors 
adversely affecting quality of life.[38-40] The need to manage pain was one of the highest-scoring 
items on the survey, but there was a lack of consensus about whether coeliac plexus neurolysis 
(CPN) should be discussed before embarking on any surgical procedure. CPN can prevent pain 
development for up to 6 months post-operatively[41] and, while some studies suggest that CPN may 
not offer greater pain relief over opioid analgesia, it has fewer side effects.[40] The NCCN guidelines 
do suggest that CPN should be considered at the time of palliative surgery.   
A major strength of this study was the robust method we used to elicit opinions from experts in 
pancreatic cancer management.[42, 43] Key features of the Delphi process we used included: (1) the 
multi-disciplinary panel drawn from a wide range of medical and allied health fields; (2) each health 
professional rated the quality-of-care statements anonymously, limiting the potential for a single 
individual to dominate the proceedings; (3) we provided structured feedback, where following the 
first round of ratings the panel received the ratings from the entire group; (4) it was  iterative, with 
two rating rounds allowing panel members to change their minds after deliberation;[16] (5) it was 
internet-based and therefore less costly than other methods such as focus groups. 
The study has two key limitations. Firstly, although a broad range of specialist clinicians participated, 
response rates were highly variable and some specialties (notably gastroenterology) were under-
represented. For ethical reasons we were unable to capture detailed information about the non-
responders so it is difficult to determine the representativeness of the final sample in terms of 
factors such as location of practice and years of experience. Secondly, some statements did not fully 
portray the clinical variability that underlies decisions about care. This particularly applies to those 
statements which commenced with the words "All patients".  While the statements had been 
transcribed verbatim following responses to the open-ended questionnaire and to amend them 
would have resulted in a deviation from the Delphi method, some items may have scored more 
consistently had they been worded differently.  
This work shows that, for the most part, clinicians’ opinions reflect clinical guideline-recommended 
care, albeit with some exceptions. However, clinicians identified a number of additional factors that 
are not incorporated in pancreatic-cancer specific guidelines, with a particular focus on where 
patients should be treated, the importance of clear communication and the need for 
multidisciplinary care. The lack of agreement about which patients and clinicians should be included 
in MDT meetings reinforces the notion that further in-depth investigations are required to identify 
the optimal composition and schedule of MDT meetings to improve and standardise practice in this 
area. Similarly, clinicians support the need to develop policies about transfer to tertiary centres and 
implementation of Telehealth to ensure that all patients with pancreatic cancer receive optimal 
multidisciplinary coordinated care.  
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